Miltenyi Biotec, Gmbh

Miltenyi Biotech B.v. & Co. Kg

Mab Factory Gmbh

Miltenyi Biotec B.v. Co., Kg

Technische Universitat Braunschweig

Dübel, Stefan

Holger Thie

Christophe De Romeuf

Andrew Kaiser

Volker Nolle

Stefan Dübel

Christian Behrens

Lars Toleikis

Michael Hust

Iris Bürger

Stefan Tomiuk

Thomas Schirrmann

Kristina Reck

Sarah-Jane Kellmann

Volker Nölle

The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Cabinding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Cabinding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.

Composition and method for affecting the binding of antigen-binding polypeptides to antigens

The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.

Humanized antibody or fragment thereof specific for CD45R0

Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.

Recombinant anti-MUC1 antibodies

The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein.

Generating metal ion binding proteins

Growing community of inventors

Biberach an der Riss, Germany

Holger Thie